Key Drivers Behind AbbVie’s (ABBV) Performance — May 23rd, 2025

RS Investments, an investment management company, released its “RS Large Cap Value Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its benchmark, the Russell 1000 Value Index (the “Index”),...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit – ABBV — May 16th, 2025

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut. — May 18th, 2025

Key Points AbbVie's earnings are down nearly 70% since its pandemic highs. Medtronic has increased its dividend for 47 consecutive years. Pfizer has an outsized dividend yield of 7.5% that's potentially unsustainable. 10 stocks we like better than Pfizer › Dividend stocks can be a smar...

The Zacks Analyst Blog Highlights Bayer, Novo Nordisk, GSK, Merck and AbbVie — May 19th, 2025

For Immediate Release Chicago, IL – May 19, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog incl...

Pharma Stock Roundup: BAYRY Q1 Earnings, NVO & GSK's New Deals — May 16th, 2025

This week, Bayer BAYRY announced first-quarter 2025 results. Novo Nordisk NVO and GSK plc GSK announced licensing deals with smaller biotechs. The FDA granted approval to Merck’s MRK drug, Welireg, for its third indication in the United States and AbbVie’s ABBV Emrelis, its first inter...

Jim Cramer On AbbVie: Makes “Sense To Start a Position in the Stock” — May 16th, 2025

Calling AbbVie Inc. (NYSE:ABBV) one of his “absolute favorites” during the recent episode of Mad Money, Cramer said: “Or how about one of my absolute favorites right here too, AbbVie. Now here's a drug company with no patent cliff in sight whatsoever. Got tremendous franchises in ne...

Top 15 investment grade bond issuers — Jun 1st, 2025

[A man examines the inscription Bonds with a magnifying glass. Assessment of the value and profitability of securities. Investment. Terms and conditions. Face value. Raise money to finance new projects] Andrii Yalanskyi/iStock via Getty Images Investment grade credit (NYSEARCA:LQD [https:...

AbbVie Partners with Chicago Cubs on "Striking Out Cancer" — May 30th, 2025

Chicago-based institutions aim to create greater awareness for cancer advocacy and to support non-profit cancer organizations NORTH CHICAGO, Ill., May 30, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced a multi-year partnership with the Chicago Cubs to support people living with cancer...

ABBV Quantitative Stock Analysis — Jun 3rd, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momen...

The Gross Law Firm Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – ABBV — May 15th, 2025

NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible l...

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 — May 27th, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. Over the next few years, therapeutic companies, which develop a wide variety of treatments for diseases and disord...

High Growth Tech Stocks To Watch In The US June 2025 — Jun 3rd, 2025

Over the last 7 days, the United States market has risen by 2.0% and is up 12% over the past year, with earnings forecasted to grow by 14% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potentia...

Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc. (ABBV) — Jun 4th, 2025

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible ...

Pfizer Signs Experimental Drug Licensing Agreement With 3SBio — May 20th, 2025

Pharmaceutical giant Pfizer Inc. PFE has signed a significant licensing agreement with China's 3SBio Inc. for an experimental cancer drug, SSGJ-707. According to the deal, Pfizer will pay $1.25 billion upfront and could pay up to an additional $4.8 billion contingent upon achieving certain...

AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient — May 22nd, 2025

Following a national competition, AbbVie and SpinUp – the University of Toronto's lab-based, life sciences accelerator – announce Neuropeutics Inc as recipient of first AbbVie Biotech Innovators Award Neuropeutics Inc receives a year of laboratory space and equipment at no cost, as we...

AbbVie (ABBV) Soared on Favorable Tailwinds — May 20th, 2025

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.  The S&P 500 Index ended Q1 down 4.3%, marking a turbulent start to 2025. The volatility that ...

1 Healthcare Stock to Keep an Eye On and 2 to Ignore — May 16th, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks ...

FDA launches Elsa, an AI tool designed to accelerate agencywide operations — Jun 3rd, 2025

[FDA headquarters in Washington DC.] JHVEPhoto The U.S. Food and Drug Administration (FDA) has launched Elsa, an AI tool designed to modernize and speed up agency-wide operations ranging from scientific reviews to investigations. Marty Makary, the head of the agency, announced the launch...

3 Value Stocks Facing Headwinds — May 22nd, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great de...

Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play — May 22nd, 2025

Investing.com-- French pharmaceutical giant Sanofi SA (EPA:SASY) said on Wednesday it had entered an agreement to buy U.S.-listed biotech firm Vigil Neuroscience Inc (NASDAQ:VIGL), with focus chiefly on an early-stage Alzheimer’s drug being developed by the firm. Sanofi will pay $8 in...

AbbVie (ABBV) Gains As Market Dips: What You Should Know — May 30th, 2025

In the latest trading session, AbbVie (ABBV) closed at $186.11, marking a +0.26% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.01%. Elsewhere, the Dow saw an upswing of 0.13%, while the tech-heavy Nasdaq depreciated by 0.32%. Coming into today,...

AbbVie to Present at the Goldman Sachs 46th Annual Global Healthcare Conference — Jun 3rd, 2025

NORTH CHICAGO, Ill., June 3, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025. Management will participate in a fireside chat at 10:20 a.m. Central time. A live audio webcast of the presentati...

3 Value Stocks Facing Headwinds — May 22nd, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great de...

Cerevel Therapeutics Holdings, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – ABBV — May 21st, 2025

NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Cerevel Therapeutics Holdings, Inc. (NYSE: ABBV). Shareholders who purchased shares of ABBV during the class period listed are encouraged to contact the firm regarding possible l...

1 Healthcare Stock to Keep an Eye On and 2 to Ignore — May 16th, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks ...

Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc. (ABBV) of a Class Action Lawsuit and an Upcoming Deadline — May 22nd, 2025

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

3 Cheap Dividend Growth Stocks to Buy Right Now — Jun 4th, 2025

Key Points These stocks all pay dividends that yield more than 3%. All three are fairly cheap options, trading at modest earnings multiples. They have also been increasing their dividend payments annually for more than a decade. 10 stocks we like better than AbbVie › Dividend growth st...

AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer — May 15th, 2025

AbbVie ABBV announced that the FDA has granted accelerated approval to its antibody-drug conjugate (ADC), telisotuzumab vedotin (or Teliso-V), for treating certain patients with non-small cell lung cancer (NSCLC). The drug will be marketed under the brand name Emrelis. Under this approval...

AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit — May 23rd, 2025

AbbVie Inc. (NYSE:ABBV) has achieved a significant legal victory as the Illinois Appellate Court upheld the dismissal of a shareholder class action lawsuit stemming from its $63 billion acquisition of Allergan plc in 2020.AbbVie Inc. (NYSE:ABBV) Scores Major Legal Victory as Illinois Court...

Some May Be Optimistic About AbbVie's (NYSE:ABBV) Earnings — May 16th, 2025

AbbVie Inc.'s (NYSE:ABBV) stock was strong despite it releasing a soft earnings report last week. We think that investors might be looking at some positive factors beyond the earnings numbers. This technology could replace computers: discover the 20 stocks are working to make quantum comp...

AbbVie and ADARx Pharmaceuticals Announce Collaboration and License Option Agreement to Develop Next-Generation siRNA Therapies Across Multiple Therapeutic Areas — May 14th, 2025

- Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies across neuroscience, immunology and oncology NORTH CHICAGO, Ill. and SAN DIEGO, May 14, 2025 ...

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? — May 28th, 2025

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this drugmaker have returned -4%, compared to the Zacks S&P 500 composi...

AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers — May 28th, 2025

AbbVie recently unveiled promising data on its investigational therapies, including the novel c-Met-targeting ADC, Temab-A, and the SEZ6-directed ADC, ABBV-706, indicating progress in their clinical pipelines. Despite these announcements, AbbVie's stock price remained flat, aligned with ov...

Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks — Jun 4th, 2025

An updated edition of the April 14, 2025 article. The global population is aging at an unprecedented pace, reshaping healthcare systems and economic planning across nations. Longer life expectancies—fueled by medical advancements and improved living standards—have coincided with decli...

ABBV Crosses Above Key Moving Average Level — Jun 4th, 2025

In trading on Wednesday, shares of AbbVie Inc (Symbol: ABBV) crossed above their 200 day moving average of $189.11, changing hands as high as $190.18 per share. AbbVie Inc shares are currently trading up about 0.7% on the day. The chart below shows the one year performance of ABBV shares...

AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat — May 29th, 2025

AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective res...

ABBV Factor-Based Stock Analysis — Jun 4th, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momen...

AbbVie (ABBV) has a Stable and Highly Profitable Business Model — May 22nd, 2025

Renaissance Investment Management, an investment management company, released its Q1 2025 “Large Cap Growth Strategy” investor letter. A copy of the letter can be downloaded here. The S&P 500 experienced a 4.3% loss in Q1 due to uncertainty in technology stock valuations and US economi...

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact Levi & Korsinsky — May 30th, 2025

NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

FDA Fast-Tracks AbbVie's New Lung Cancer Therapy Emrelis For Tough Lung Cancer Cases — May 14th, 2025

The U.S. Food and Drug Administration (FDA) granted accelerated approval to AbbVie Inc.’s (NYSE:ABBV) Emrelis (telisotuzumab vedotin-tllv) for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE)...

Guru Fundamental Report for ABBV — Jun 1st, 2025

Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our Multi-Factor Investor model based on the published strategy of Pim van Vliet. This multi-factor model seeks low volatility stocks that also have strong momen...

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals — Jun 3rd, 2025

The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with three approved products designed to meet patient needs across the spectrum of migraine, AbbVi...

The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands — May 30th, 2025

For Immediate Release Chicago, IL – May 30, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog incl...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc. (ABBV) Shareholders — May 19th, 2025

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel Therapeutics Holdings, Inc." or the "Company") (NYSE: ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on...

2 Incredible Dividend Growth Stocks to Buy Now — May 21st, 2025

Key Points Dividend growth stocks often deliver returns that are superior to the benchmark S&P 500. AbbVie and W.W. Grainger are elite dividend growth stocks that would be solid additions to any income-focused portfolio. 10 stocks we like better than AbbVie › Dividend growth stocks hav...

Sanofi to acquire Vigil Neuroscience in Alzheimer’s drug play — May 22nd, 2025

Investing.com-- French pharmaceutical giant Sanofi SA (EPA:SASY) said on Wednesday it had entered an agreement to buy U.S.-listed biotech firm Vigil Neuroscience Inc (NASDAQ:VIGL), with focus chiefly on an early-stage Alzheimer’s drug being developed by the firm. Sanofi will pay $8 in...

AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio — May 27th, 2025

- Key oral presentations highlight new data from AbbVie's novel investigational antibody-drug conjugates (ADCs) including telisotuzumab adizutecan (ABBV-400, Temab-A) in advanced non-small cell lung cancer (NSCLC), ABBV-706 in high-grade neuroendocrine neoplasms (NENs) and pivekimab suniri...

AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit — May 23rd, 2025

AbbVie Inc. (NYSE:ABBV) has achieved a significant legal victory as the Illinois Appellate Court upheld the dismissal of a shareholder class action lawsuit stemming from its $63 billion acquisition of Allergan plc in 2020.AbbVie Inc. (NYSE:ABBV) Scores Major Legal Victory as Illinois Court...

AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel — May 22nd, 2025

AbbVie experienced a 6.8% share price increase over the past month, coinciding with several significant corporate events. The company announced a collaboration with ADARx Pharmaceuticals to develop siRNA therapeutics, as well as FDA approval for EMRELIS™ in treating lung cancer, indicati...

3 Cheap Dividend Growth Stocks to Buy Right Now — Jun 4th, 2025

Dividend growth stocks can be ideal long-term options for any investment portfolio. That's because they not only offer a good payout, but they may also rise over time, helping offset the negative effects of inflation. In a best-case scenario, your inflation-adjusted income ends up rising o...